HIV vaccine acceptability: A systematic review and meta-analysis

AIDS

Volumn 24, Issue 11, 2010, Pages 1749-1756

  Newman, Peter A ^a   Logie, Carmen ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

acceptability of healthcare; cost; efficacy; health services accessibility; HIV vaccines; meta analysis; risks and benefits; systematic review

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

CORRELATION ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRUG UTILIZATION; ETHNICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION SENSITIVITY; INFORMATION PROCESSING; INFORMATION RETRIEVAL; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

AIDS VACCINES; HIV INFECTIONS; HUMANS; PATIENT ACCEPTANCE OF HEALTH CARE; RESEARCH DESIGN; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 77954318214     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833adbe8     Document Type: Review

References (58)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 Infection in Thailand. N Engl J Med 2009; 361:2209-2220.
2. Dolin R. HIV vaccine trial results-an opening for further research. N Engl J Med 2009; 361:2279-2280.
3. Fauci AS, Johnston MI, Dieffenbach CW, Burton DR, Hammer SM, Hoxie JA, et al. HIV vaccine research: the way forward. Science 2008; 321:530-532.
4. Esparza J, Osmanov S. HIV vaccines: a global perspective. Curr Mol Med 2003; 3:183-193.
5. Newman PA, Lee SJ, Duan N, Rudy E, Nakazono TK, Boscardin J, et al. Preventive HIV vaccine acceptability and behavioral risk compensation among a random sample of high-risk adults in Los Angeles (L. A. VOICES). Health Serv Res 2009; 44:2167-2179.
6. Hu DJ, Vitek CR, Bartholow B, Mastro TD. Key issues for a potential human immunodeficiency virus vaccine. Clin Infect Dis 2003; 36:638-644.
7. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive meta-analysis, a computer program for meta analysis. pp. 1-8. 2005. http://www.Meta-Analysis.com. [Accessed 19 November 2009]
8. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Eggar M, Smith GD, Altman DG, e-ditors. Systematic reviews in healthcare: meta-analysis in context. 2nd ed. London: BMJ Books; 2001. pp. 285-312.
9. Streiner DL. Meta-analysis: a 12-step program. Electron J Gambl Issues 2003; 1. http://www.camh.net/egambling/issue9v1/fea-ture/. (Accessed 19 November 2009)
10. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 2006; 11:93-206.
11. Allen MA, Liang TS, La Salvia T, Tjugum B, Gulakowski RJ, Murguia M. Assessing the attitudes, knowledge and awareness of HIV vaccine research among adults in the United States. J Acquir Immune Defic Syndr 2005; 40:617-624.
12. Bishai D, Pariyo G, Ainsworth M, Hill K. Determinants of personal demand for an AIDS vaccine in Uganda: contingent valuation survey. Bull World Health Organ 2004; 82:652-660.
13. Crosby RA, Holtgrave DR, Bryant L, Frew PM. Factors associated with the acceptance of an AIDS vaccine: an exploratory study. Prev Med 2004; 39:804-808.
14. Crosby RA, Holtgrave DR, Bryant L, Frew PM. Correlates of negative intent to receive an AIDS vaccine: an exploratory study. Int J STD AIDS 2004; 15:552-557.
15. Gagnon M, Godin G. Young adults and HIV vaccine: determinants of the intention of getting immunized. Can J Public Health 2000; 91:432-434.
16. Hom DL, Johnson JL, Mugyenyi P. HIV-1 risk and vaccine acceptability in the Ugandan military. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15:375-380.
17. Kakinami L, Newman PA, Lee SJ, Duan N. Differences in HIV vaccine acceptability between genders. AIDS Care 2008; 20:542-546.
18. Lally M, Gaitanis M, Vallabhaneni S, Reinert S, Mayer K, Zimet G, et al. Willingness to receive an HIV vaccine among incarcerated persons. Prev Med 2006; 43:402-405.
19. Liau A, Zimet G, Fortenberry J. Attitudes about human immunodeficiency virus immunization: the influence of health beliefs and vaccine characteristics. Sex Transm Dis 1998; 25:76-81.
20. Liau A, Zimet G. Undergraduates? perception of HIV immunization: attitudes and behaviours as determining factors. Int J STD AIDS 2000; 11:445-450.
21. Liau A, Zimet G. The acceptability of HIV immunization: examining vaccine characteristics as determining factors. AIDS Care 2001; 13:643-650.
22. Mays R, Zimet G. Recommending STI vaccination to parents of adolescents: the attitudes of nurse practitioners. Sex Transm Dis 2004; 31:428-432.
23. Newman PA, Duan N, Cunningham WE, Rudy ET, Lee SJ, Seiden D. HIV vaccine acceptability among communities at risk: the impact of vaccine characteristics. Vaccine 2006; 24:2094-2101.
24. Newman PA, RoungprakhonS, Tepjan S, Yim S. Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand. Vaccine 2010; 28:958-964.
25. Ritvo P, Irvine J, Klar N, Wilson K, Brown L, Bremner K, et al. A Canadian national survey of attitudes and knowledge regarding preventive vaccines. J Immune Based Ther Vaccines 2003; 1:3.
26. Zimet G, Fortenberry JD, Blythe M, Dairaghi J, Schering S. Health beliefs and vaccine characteristics predict HIV vaccine acceptance among adolescent patients. J Adolesc Health 1996; 18:148.
27. Zimet G, Liau A, Fortenberry JD. Health beliefs and intention to get immunized for HIV. J Adolesc Health 1997; 20:354-359.
28. Zimet G, Fortenberry JD, Blythe MJ. Adolescents? attitudes about HIV immunization. J Pediatr Psychol 1999; 24:67-75.
29. Zimet G, Blythe MJ, Fortenberry JD. Vaccine characteristics and acceptability of HIV immunization among adolescents. Int J STD AIDS 2000; 11:143-149.
30. Zimet G, Perkins SM, Sturm LA, Bair RM, Juliar BE, Mays RM. Predictors of STI vaccine acceptability among parents and their adolescent children. J Adolesc Health 2005; 37:179-186.
31. Barrington C, Moreno L, Kerrigan D. Local understanding of an HIV vaccine and its relationship with HIV-related stigma. AIDS Care 2007; 19:871-877.
32. Barrington C, Moreno L, Kerrigan D. Perceived influence of an HIV vaccine on sexual-risk behavior in the Dominican Republic. Cult Health Sex 2008; 10:391-401.
33. Frew P, Crosby RA, Salazar LF, Gallinot LP, Bryant LO, Holt-grave DR. Acceptance of a potential HIV/AIDS vaccine among minority women. J Natl Med Assoc 2008; 100:802-813.
34. Griffin DK, Nyamathi A, Tallen L, Gonzalez-Figueroa E, Dominick E. Breaking the silence: what homeless 18-to 24-year-olds say about HIV vaccine trials. J Healthcare Poor Underserved 2007; 18:687-698.
35. Lee SJ, Brooks RA, Newman PA, SeidenD, SangthongR, Duan N. HIV vaccine acceptability among immigrant Thai residents in Los Angeles: a mixed-method approach. AIDS Care 2008; 20:1161-1168.
36. Lindegger G, Quayle M, Ndlovu M. Local knowledge and experiences of vaccination: implications for HIV-preventive vaccine trials in South Africa. Health Educ Behav 2007; 34:108-123.
37. Mays RM, Sturm LA, Zimet GD. Parental perspectives on vaccinating children against sexually transmitted infections. Soc Sci Med 2004; 58:1405-1413.
38. Newman PA, Duan N, Rudy ET, Johnston-Roberts K. HIV risk and prevention in a postvaccine context. Vaccine 2004; 22:1954-1963.
39. Newman PA, Duan N, Rudy ET, Roberts KJ, Swendeman D. Posttrial HIV vaccine adoption: concerns, motivators, and intentions among persons at risk for HIV. J Acquir Immune Defic Syndr 2004; 3:1393-1403.
40. Newman PA, Seiden DS, Roberts KJ. A small dose of HIV? HIV vaccine mental models and risk communication. Health Educ Behav 2009; 36:321-333.
41. Nguyen F. Gauging the acceptability of HIV vaccines: an exploratory study examining knowledge, attitudes, and beliefs among injecting drug users in Viet Nam. J Ethnic Cultur Diversity Soc Work 2007; 16:161-192.
42. Nodin N, Carballo-Dieguez A, Ventuneac AM, Balan IC, Re-mien R. Knowledge and acceptability of alternative HIV prevention bio-medical products among MSM who bareback. AIDS Care 2008; 20:106-115.
43. Roberts KJ, Newman PA, Duan N, Rudy ET. HIV vaccine knowledge and beliefs among communities at elevated risk: conspiracies, questions and confusion. J Natl Med Assoc 2005; 97:1662-1671.
44. Rudy ET, Newman PA, Duan N, Kelly EM, Roberts KJ, Seiden DS. HIV vaccine acceptability among women at risk: perceived barriers and facilitators to future HIV vaccine uptake. AIDS Educ Prev 2005; 17:253-267.
45. Salazar LF, Holtgrave D, Crosby RA, Frew P, Peterson JL. Issues related to gay and bisexual men?s acceptance of a future AIDS vaccine. Int J STD AIDS 2005; 16:546-548.
46. SaylesJ, Macphail C, Newman PA, Cunningham W. Future HIV vaccine acceptability among young adults in South Africa. Health Educ Behav 2009. doi: 10. 1177/1090198109335654.
47. Webb PM, Zimet GD, Fortenberry JD, Mays R. Having sex with anyone and everything: anticipated reactions to HIV immunization. J Adolesc Health 1997; 20:128.
48. Webb PM, Zimet GD, Mays R, Fortenberry JD. HIV immunization: acceptability and anticipated effects on sexual behavior among adolescents. J Adolesc Health 1999; 25:320-322.
49. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21:1539-1558.
50. Cohen J. A power primer. Psychol Bull 1992; 112:155-159.
51. Newman PA, Duan N, Rudy ET, Anton PA. Challenges for HIV vaccine dissemination and clinical trial recruitment: if we build it, will they come? AIDS Patient Care STDS 2004; 18: 691-701.
52. Duan N. Listening to consumers and HIV vaccine preparedness. Lancet 2005; 365:1119-1121.
53. Mclean AR, Blower SM. Imperfect vaccines and herd immunity to HIV. Proc Biol Sci 1993; 253:9-13.
54. Blower SM, Bodine EN, Grovit-Ferbas K. Predicting the potential public health impact of disease-modifying HIV vaccines in South Africa: the problem of clades. Curr Drug Targets Infect Disord 2005; 5:179-192.
55. Streefland PH. Introduction of a HIV vaccine in developing countries: social and cultural dimensions. Vaccine 2003; 21:1304-1309.
56. Brooks R, Newman PA, Ortiz D, Duan N. HIV vaccine trial preparedness among Spanish-speaking Latinos in the United States. AIDS Care 2007; 19:52-58.
57. Elias C, Coggins C. Acceptability research on female-controlled barrier methods to prevent heterosexual transmission of HIV: Where have we been? Where are we going?. J Womens Health Gend Based Med 2001; 10:163-173.
58. UNAIDS/WHO. Global facts and figures; 2009. http://data. unaids.org/pub/FactSheet/2009/20091124-FS-global-en.pdf.